IBO Impact BioMedical Inc.
Mergers ·
Zoar Limited filed a Form F-4 on September 10, 2026 that includes Impact BioMedical's preliminary proxy statement for the proposed business combination with Zoar Labs Limited.
Impact BioMedical agreed on June 21, 2025 to a reverse merger with Dr Ashleys, after which Impact holders would own 4.80% of the combined company. Closing needs shareholder approval, an effective registration statement and NYSE American listing approvals.
The combined company would trade on the NYSE American as Dr Ashleys Limited. The deal needs Impact BioMedical shareholder approval.
Impact BioMedical Inc. discovers, confirms and patents science and technologies that partners can develop into healthcare and wellness offerings through licensing, co-development, joint ventures and other relationships. It trades on the NYSE American. Its principal subsidiaries include Impact BioLife Science, Inc., Global BioMedical, Inc., Global BioLife, Inc. and Sweet Sense, Inc. Its Linebacker platform is a family of small molecule polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders and neurology, and Linebacker-1 and Linebacker-2 have been licensed to ProPhase Laboratories (NASDAQ: PRPH). Laetose is a patented formulation that the company says could reduce caloric intake and glycemic index in foods, and it is seeking partners for it. Functional Fragrance Formulation (3F) is a suite of fragrances with botanical ingredients, developed with Chemia Corporation of St. Louis, MO. Equivir is a polyphenol blend with potential antiviral effects, also licensed to ProPhase Laboratories for over-the-counter upper respiratory wellness. The company reports sixty (60) issued and over sixty (60) pending patents at the end of 2025.
| Product or program | What it is | Stage |
|---|---|---|
| Linebacker | Small molecule polyphenol platform for oncology, inflammatory disorders and neurology | |
| Laetose | Patented formulation said to reduce caloric intake and glycemic index in foods | Composition patent allowed in the United States |
| Functional Fragrance Formulation (3F) | Suite of functional fragrances with botanical ingredients, partnered with Chemia | Composition patents issued in the U.S.; pending in other countries |
| Equivir | Polyphenol blend with antiviral effects, licensed to ProPhase Laboratories |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $32,000 | |
| Research and development | $340,000 | $278,000 |
| Net income (loss) | -$11.8 million | -$24.7 million |
| Cash from operations | -$1.9 million | -$2.9 million |
| Cash and equivalents | $3,000 | $2.0 million |
Our latest story on this, dated Jun 23, 2025: "Impact BioMedical signs reverse merger agreement with Dr Ashleys Limited". The story links the filing or release it is based on. Read the story.
Impact BioMedical Inc. trades under the ticker IBO on AMEX.
Impact BioMedical Inc. is listed on AMEX.
The SEC Central Index Key (CIK) for Impact BioMedical Inc. is 1834105. Its filings are on SEC EDGAR.
107,821,231 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-07.
Our directory records Impact BioMedical Inc. under United States.
Our directory classifies Impact BioMedical Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Impact BioMedical Inc. is US45259L3042.
aibio.space lists Impact BioMedical Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
Impact BioMedical Inc. discovers, confirms and patents science and technologies that partners can develop into healthcare and wellness offerings through licensing, co-development, joint ventures and other relationships. It trades on the NYSE American.
Linebacker: Small molecule polyphenol platform for oncology, inflammatory disorders and neurology Stage: Not stated in text.
Laetose: Patented formulation said to reduce caloric intake and glycemic index in foods Stage: Composition patent allowed in the United States.
$32,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Impact BioMedical Inc. reported a net loss of $11.8 million for the fiscal year ended Dec 31, 2025, and used $1.9 million of cash in operations, per its annual report to the SEC.
Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,9.01). Source
Filed documents for a merger or acquisition. SEC Form 425. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio